The Federal Circuit's recent ruling that patents listed in the FDA's Orange Book must cover the active ingredient of a drug has sparked significant debate in the pharmaceutical industry. The court's ...

Teva sued Amneal for patent infringement under the Hatch-Waxman Act after receiving notice Amneal sought to sell a generic version of Teva’s ProAir HFA inhaler product. Teva’s ProAir HFA is a ...

In elderly patients with sufficient cognitive function, manual dexterity, and hand strength, the most influential factors in inhaler selection are cost reimbursement, device availability ...

Teva holds an approved NDA for its ProAir® HFA Inhalation Aerosol product, which permits Teva to market and sell an inhaler device that administers the API albuterol sulfate. Teva listed several ...